Updated Date: Mon, 03 Jan 2022 00:00:00 EST

Updated Date: Mon, 03 Jan 2022 00:00:00 EST

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid’s patent cliff esagonowsky Mon, 01/10/2022 – 14:27

What you need to knowOverall survival of babies born extremely preterm has improved in recent years, but evidence […]

The UK has seen a flurry of activity recently in relation to illegal drugs. The government published its […]

#JPM22, Day 1: Bristol Myers Squibb’s blockbuster losses of exclusivity, Novartis’ spending plans and more esagonowsky Mon, 01/10/2022 […]

Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo kdunleavy Mon, 01/10/2022 – […]

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe fkansteiner Mon, 01/10/2022 – 08:42

JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launch fkansteiner Mon, 01/10/2022 […]

JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+ esagonowsky […]